Clinical Cancer Research, Vol 2, Issue 1 43-46, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Limited sampling model for area under the concentration time curve of total topotecan

H Minami, JH Beijnen, J Verweij and MJ Ratain
Department of Medicine, Committee on Clinical Pharmacology, and Cancer Research Center, University of Chicago, Chicago, Illinois 60637-1470, USA.

Antitumor activity of topotecan, a new derivative of camptothecin, has been documented in many tumors. The active lactone form of topotecan is in equilibrium with the inactive hydroxyacid form. However, dose-limiting toxicity, neutropenia, is correlated to the area under the concentration time curve (AUC) of not only the lactone form but also total (lactone + hydroxyacid) topotecan. Because the determination of the total topotecan plasma concentration is technically much easier than the lactone, we sought to establish a limited sampling model for the AUC of total topotecan. Thirty-four pharmacokinetic profiles were obtained in 19 patients in a Phase I study of topotecan, which was infused over 30 min for 5 days. Multiple regression models predicting the AUC were developed using 17 profiles and validated using the rest of the data. The best model was: AUCpred (ng x h/ml) = 1.75 x C15m (ng/ml) + 11.2 x C6h (ng/ml) + 7.90 x dose (mg/m2), where AUCpred was the AUC predicted by the model, and C15m and C6h were the measured concentrations of total topotecan at 15 min and 6 h after the end of infusion, respectively. When this model was validated, it was unbiased (percentage of mean predicted error +/- SE, -1.0 +/- 3.3%) and precise (percentage of root mean square error, 11%). Because this model requires only two concentrations of total topotecan to estimate the AUC, it will be useful for further pharmacodynamic evaluation of topotecan in multi-institutional studies.

This article has been cited by other articles:

				L. Alnaim Therapeutic drug monitoring of cancer chemotherapy Journal of Oncology Pharmacy Practice, December 1, 2007; 13(4): 207 - 221. [Abstract] [PDF]

				J. C. Panetta, L. C. Iacono, P. C. Adamson, and C. F. Stewart The Importance of Pharmacokinetic Limited Sampling Models for Childhood Cancer Drug Development Clin. Cancer Res., November 1, 2003; 9(14): 5068 - 5077. [Abstract] [Full Text] [PDF]

				A. Sparreboom, M. J. A. de Jonge, C. J. A. Punt, W. J. Loos, K. Nooter, G. Stoter, M. G. Porro, and J. Verweij Prediction of the Systemic Exposure to Oral 9-Amino-20(S)-Camptothecin Using Single-Sample Analysis Drug Metab. Dispos., July 1, 1999; 27(7): 816 - 820. [Abstract] [Full Text]